Literature DB >> 23643401

Natural antiband 3 antibodies in patients with sickle cell disease.

Rinaldo Villaescusa1, Ada Amalia Arce, Marie-Laure Lalanne-Mistrih, Yann Lamarre, Régine Hierso, Carlos Hernández, Marie-Dominique Hardy-Dessources.   

Abstract

Band 3 oligomers, precociously formed in the membrane of sickle red blood cells (SS RBC) as a result of oxidative damage, induce two significant changes: (1) contribution to the adhesive nature of these cells to endothelial cells; (2) production of recognition sites for natural antiband 3 antibodies (antiband 3 Nabs). The inhibition of the adhesion of SS RBC to endothelial cells by band 3 peptides suggests a participation of antiband 3 Nabs in the etiology and prevention of vaso-occlusive crises (VOC). To address this question, we measured the levels of antiband 3 Nabs in sickle cell anaemia (SCA) patients (45 in steady state, 35 in VOC) and in controls (27 sickle trait, 30 normal AA subjects). A significant decreased of antiband 3 Nabs in the VOC group was demonstrated as compared with the steady state group, the sickle trait and healthy controls. This study provides data suggesting that Antiband 3 Nabs are likely to play a role in the SCA VOC.
Copyright © 2012 Académie des sciences. Published by Elsevier SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23643401     DOI: 10.1016/j.crvi.2012.09.002

Source DB:  PubMed          Journal:  C R Biol        ISSN: 1631-0691            Impact factor:   1.583


  1 in total

1.  CAREST--Multilingual Regional Integration for Health Promotion and Research on Sickle Cell Disease and Thalassemia.

Authors:  Jennifer Knight-Madden; Marc Romana; Rinaldo Villaescusa; Marvin Reid; Maryse Etienne-Julan; Laurence Boutin; Gisèle Elana; Narcisse Elenga; Gillian Wheeler; Ketty Lee; Rosa Nieves; Althea Jones Lecointe; Marie-Laure Lalanne-Mistrih; Gylna Loko; Lisiane Keclard-Christophe; Marie-Dominique Hardy-Dessources
Journal:  Am J Public Health       Date:  2016-03-21       Impact factor: 9.308

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.